News
Article
AJMC® in the Press, December 6, 2024
Author(s):
Key Takeaways
- A phase 3 trial for isatuximab showed one of the lowest Black participant rates in two decades, highlighting diversity issues in clinical trials.
- Vertical integration in cardiology has resulted in higher Medicare costs with minimal evidence of quality improvement, as presented at the AHA Scientific Sessions 2024.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A feature article published in Evidence-Based Oncology™, a special issue publication of The American Journal of Managed Care® (AJMC®), was highlighted in a piece by Stat. The article, “As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?” highlighted the lack of diversity in a recent phase 3 clinical trial for isatuximab, a treatment approved for multiple myeloma. The clinical trial had among the lowest rates of Black participants in the past 2 decades.
An article from Becker’s ASC Review highlighted conference coverage published on AJMC.com, the website of AJMC. The article, “Vertical Integration in Cardiology Brings Less Value, Analysis Finds,” reported on a poster session held at the American Heart Association Scientific Sessions 2024, where presentations included the finding that vertical integration has led to higher costs in Medicare with little evidence of an increase in quality.
An article from Midland Daily News referenced an article published on AJMC.com. The article, “Infant Mortality Increases Across US Following Dobbs Decision,” reported that a 7% absolute increase in overall infant mortality and a 10% increase in infants with congenital anomalies has occurred following the Dobbs decision made by the Supreme Court, which overturned the Roe v Wade ruling that had guaranteed the legality of abortion.
